Defying the odds, Poxel plots a PhIII course for its Type 2 diabetes med and shares surge on new data
Poxel is trying to master one of the toughest acts in biotech: Develop a new drug for Type 2 diabetes and win a regulatory approval …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
